Senti Biosciences Stock (NASDAQ:SNTI)


RevenueOwnershipFinancialsChart

Previous Close

$2.18

52W Range

$1.52 - $7.43

50D Avg

$2.40

200D Avg

$3.04

Market Cap

$9.73M

Avg Vol (3M)

$21.70K

Beta

2.75

Div Yield

-

SNTI Company Profile


Senti Biosciences, Inc. operates as a gene circuit company. The company develops cell and gene therapies engineered with gene circuits that are designed to reprogram cells with biological logic to sense inputs, compute decisions, and respond to respective cellular environments. Its synthetic biology platform utilizes off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cells to target particularly challenging liquid and solid tumor oncology indications. The company's lead programs include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate acute myeloid leukemia (AML) cells, while sparing the healthy bone marrow; and SENTI-301, a multi-armed off-the-shelf CAR-NK cell therapy designed for the treatment of hepatocellular carcinoma (HCC). It also develops SENTI-401, a Logic Gated (NOT) off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer (CRC) cells, while sparing healthy cells in the body. The company was founded in 2016 and is based in South San Francisco, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

48

IPO Date

May 26, 2021

Website

SNTI Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22
License$800.00K

Fiscal year ends in Dec 23 | Currency in USD

SNTI Financial Summary


Dec 23Dec 22Dec 21
Revenue$2.56M$4.29M$2.29M
Operating Income$-66.77M$-70.63M$-40.45M
Net Income$-92.92M$-45.79M$-55.33M
EBITDA$-61.52M$-70.63M$-37.41M
Basic EPS$-2.09$-1.75$-1.27
Diluted EPS$-2.09$-1.75$-1.27

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison


TickerCompany
BLCMBellicum Pharmaceuticals, Inc.
MNPRMonopar Therapeutics Inc.
FHTXFoghorn Therapeutics Inc.
MLYSMineralys Therapeutics, Inc.
SABSSAB Biotherapeutics, Inc.
CVKDCadrenal Therapeutics, Inc. Common Stock
QNRXQuoin Pharmaceuticals, Ltd.
FENCFennec Pharmaceuticals Inc.
HILSTharimmune, Inc.
TYRATyra Biosciences, Inc.
CINGCingulate Inc.
CNTBConnect Biopharma Holdings Limited
XLOXilio Therapeutics, Inc.
LIPOLipella Pharmaceuticals Inc.
NLTXNeurogene Inc.
RAPTRAPT Therapeutics, Inc.